Pertussis, caused by Bordetella pertussis, remains a significant public health concern despite widespread vaccination. Antibiotic therapy plays a crucial role in eradicating bacterial carriage, reducing transmission, and mitigating disease severity when administered early. The present review analyzes the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of antibiotics recommended for pertussis treatment, including macrolides (azithromycin, clarithromycin, erythromycin) and trimethoprim-sulfamethoxazole (TMP-SMX). Data were synthesized from peer-reviewed publications, clinical guidelines, and pharmacological references. Macrolides demonstrate high intracellular penetration, prolonged half-lives (notably azithromycin), and concentration-dependent activity against B. pertussis. TMP-SMX exhibits time-dependent bacteriostatic effects by sequential inhibition of folate synthesis. Understanding PK/PD parameters such as minimum inhibitory concentration (MIC), area under the concentration–time curve (AUC), peak plasma concentration (Cmax), and time above MIC (T>MIC) is essential for optimizing dosing regimens and minimizing resistance.

pertussis, Bordetella pertussis, macrolides, azithromycin, clarithromycin, erythromycin, trimethoprim-sulfamethoxazole, pharmacokinetics, pharmacodynamics, MIC

Cherry JD. Pertussis in young infants. Pediatrics. 2016;138(3):965–972. p.965.

World Health Organization. Pertussis vaccines: WHO position paper. Weekly Epidemiological Record. 2015;90(35):433–460.

Centers for Disease Control and Prevention. Pertussis Treatment Guidelines. 2020. pp.1546–1550.

Hewlett EL, Edwards KM. Clinical practice: pertussis. New England Journal of Medicine. 2005;352:1215–1222. p.314.

Brunton LL et al. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. 2018. pp.493–518.

Andes D, Craig WA. Pharmacodynamics of macrolides. Clinical Infectious Diseases. 2002;35:112–120. pp.112–116.

Katzung BG. Basic and Clinical Pharmacology. 14th ed. 2018. pp.274–276.

Hoppe JE. Antimicrobial susceptibility of Bordetella pertussis. Antimicrobial Agents and Chemotherapy. 2000;44(4):886–889. pp.887–889.

Bush LM, Vazquez-Pertejo MT. Trimethoprim-sulfamethoxazole pharmacology. Medscape Drugs & Diseases. 2021. pp.105–108.

Wang Z et al. Macrolide-resistant Bordetella pertussis. Emerging Infectious Diseases. 2014;20(7):1181–1185. p.1185.

Eberly MD et al. Azithromycin in neonates and pyloric stenosis risk. Pediatrics. 2015;135(3):903–910. p.903.

Langley JM et al. Azithromycin safety in pediatric pertussis. Clinical Infectious Diseases. 2004;38:1119–1122. p.1122.